2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational

Program: Oral Abstract Session
Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 343-345
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Cell Expansion, Profiling, Treatment Considerations, Biological Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Microbiome, Diseases, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Research, AML, Translational Research, Study Population, Human, Animal Model
PAPER

130 Enterococcus faecium-enriched gut enterotype and LPC(16:0)-associated myeloid inflammation are linked to grade 3 CRS after CD19 CAR-T therapy in R/R B-ALL: A longitudinal multi-omics study

Jinglei Yu, MBBS, Yuqi Lv2, Mingming Zhang, PhD3, Shan Fu4, Jingjing Feng5, He Huang, MD, PhD6, Yongxian HU, MD7, Guoqing Wei8
1 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
7 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Background:

CD19 CAR-T therapy induces high remission rates in R/R B-ALL, but CRS remains a major toxicity. Antibiotic exposure and gut dysbiosis have been linked to CAR-T outcomes, but longitudinal microbiome dynamics, metabolic remodeling, and their relationships with CRS severity remain unclear. We integrated serial gut metagenomics, paired fecal/serum metabolomics and lipidomics, and functional models to investigate microbiota-metabolite-immune relationships in CAR-T-associated CRS.

Methods:

This prospective single-center study enrolled 66 patients with R/R B-ALL receiving CD19 CAR-T therapy. CRS was graded using the 2019 ASTCT criteria; grade ≥3 was defined as severe. Fecal samples were collected before FC lymphodepletion (FCb), after FC before infusion (FCa), before CRS onset (CRSb), at peak CRS (CRSp), and during recovery (CRSr). A total of 286 specimens were collected for shotgun metagenomic sequencing. Paired fecal and serum samples underwent untargeted metabolomic and lipidomic profiling.

Unsupervised species-level clustering defined enterotypes. Analyses included multivariable logistic regression, timepoint-specific enterotype-by-antibiotic interactions, bootstrap-corrected ROC curves, and mediation models. Antibiotic exposure was any antibiotic use within 4 weeks before infusion. Omics-wide comparisons were FDR-adjusted; targeted analyses used two-sided P values. LPC(16:0) was tested in a macrophage/CAR-T/Raji-GFP-Luc co-culture and in Raji-bearing SCID-beige mice given LPC(16:0) by oral gavage (10 mg/kg daily) and/or intraperitoneal injection (5 mg/kg every 2 days; n=5/group).

Results:

CRS occurred in 64/66 (97.0%), including grade 3 CRS in 19 (28.8%), with no grade ≥4 events. Three enterotypes were identified: ET1 (high-diversity, commensal-rich), ET2 (low-diversity, E. faecium-dominant), and ET3 (intermediate-diversity, Bacteroidetes-dominant). Enterotype trajectories differed by CRS severity (overall χ²=10.98, P=0.012), with grade 3 CRS more frequent with transition to or persistence of ET2 than transition from ET2 to ET1/ET3. At CRSp, ET2 was associated with higher odds of grade 3 CRS versus ET1 in univariable analysis (OR, 5.16; 95% CI, 1.48-20.83; P=0.0207). An ET2-by-antibiotic interaction was observed (OR, 5.28; 95% CI, 1.35-22.30; P=0.019). Among antibiotic-exposed patients, ET2 was associated with 8-fold higher odds of grade 3 CRS (95% CI, 2.74-26.20; P=0.0003). Associations of E. faecium abundance with grade 3 CRS were absent at FCb/FCa, emerged at CRSb (adjusted OR, 1.53; 95% CI, 1.04-2.40; P=0.043), and strengthened at CRSp (adjusted OR, 1.76; 95% CI, 1.12-3.11; P=0.025). Pre-CRS models including enterotype, antibiotic interaction, age, BMI, and baseline marrow blasts achieved bootstrap-corrected AUCs of 0.836 at FCb, 0.851 at FCa, and 0.877 at CRSb.

FDR-adjusted analyses linked ET2 to increased fecal glycerophospholipids and LPCs, decreased fecal ceramides, and enrichment of serum inflammatory lipids and glycerophospholipids. At CRSp, fecal LPC(16:0) correlated with E. faecium abundance (Spearman r=0.52, P=0.0018) and ET2 assignment (r=0.38, P=0.045). At FCa, CRSb, and CRSp, fecal LPC(16:0) was higher in patients with grade 3 CRS than in those with grade 0-2 CRS (all P<0.001). At CRSp, adjusted mediation analyses estimated that LPC(16:0) accounted for 21.7% of the ET2-grade 3 CRS association (P<0.01) and 26.1% and 18.4% of the associations of E. faecium with IFN-γ (P<0.01) and IL-6 (P<0.05), respectively.

In co-culture, macrophages increased IL-6, IL-1β, MCP-1, and G-CSF release; LPC(16:0) further increased these cytokines, TNF-α, and IFN-γ. In Raji-bearing mice, combined oral and intraperitoneal LPC(16:0) produced the greatest weight loss, hyperthermia, clinical scores ≥3, serum cytokine elevations (murine IL-6, MCP-1, and IL-1β; human IFN-γ), and M1-predominant myeloid remodeling. Two of 5 mice died after 48 hours versus none in other groups.

Conclusion: In CD19 CAR-T-treated R/R B-ALL, an E. faecium-dominant, low-diversity enterotype was associated with grade 3 CRS, particularly among patients with preinfusion antibiotic exposure. LPC(16:0) was elevated in grade 3 CRS, showed partial statistical mediation of the ET2-CRS and E. faecium-cytokine associations, and augmented myeloid inflammation in vitro and in vivo. These findings support a potential gut dysbiosis-lipid remodeling-myeloid inflammation axis in CAR-T-associated CRS and warrant independent clinical and mechanistic validation.

Jinglei Yu, MBBS: No relevant conflicts of interest to declare.